dc.contributor.author | Richardsen, Elin | |
dc.contributor.author | Andersen, Sigve | |
dc.contributor.author | Melbø-Jørgensen, Christian | |
dc.contributor.author | Rakaee, Mehrdad | |
dc.contributor.author | Ness, Nora | |
dc.contributor.author | Al-Saad, Samer | |
dc.contributor.author | Nordby, Yngve | |
dc.contributor.author | Pedersen, Mona Irene | |
dc.contributor.author | Dønnem, Tom | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Rasmussen Busund, Lill-Tove | |
dc.date.accessioned | 2019-08-02T12:44:15Z | |
dc.date.available | 2019-08-02T12:44:15Z | |
dc.date.issued | 2019-01-23 | |
dc.description.abstract | A large number of miRNAs influence key cellular processes involved in prostate tumorigenesis. Previous studies have demonstrated high expression of miRNAs in human prostate cancer (PC) tissues and cell lines. In previous microarray data, we found miR-141 to be upregulated and miR-145 to be downregulated in PC. In this large PC cohort (n = 535), we explored the prognostic role of miR-141 and miR-145 in PC. Tumor epithelial (TE) and tumor stromal (TS) areas were evaluated separately and combined (TE + TS). <i>In situ</i> hybridization was used to evaluate the expression of the miRNAs. We found that miR-141 (TE) correlated significantly to Gleason score ≥8 (p = 0.040) and large tumor size (≥20 mm, p = 0.025) and miR-141 (TE + TS) to Gleason grade (p = 0.001). MiR-145 correlated to pT-stage (p = 0.038), tumor size (p = 0.025), Gleason grade (p = 0.051) and PSA (p = 0.032). In univariate analysis miR-141 (TE + TS) was significantly associated with biochemical failure-free survival (BFFS, p = 0.007) and clinical failure-free survival (CFFS, p = 0.021). For miR-145, there were no differences between patients with high versus low expression. In multivariate analysis overexpression of miR-141 in tumor epithelium and tumor stroma was significantly associated with BFFS (HR = 1.07 CI95% 1.00–1.14, p = 0.007). To conclude, high expression of miR-141 appears associated with increased risk of biochemical PC recurrence. | en_US |
dc.description.sponsorship | Norwegian Cancer Society (www.krefforeningen.no)
The Northern Health Administration (www.helse-nord.no)
UiT Arctic University of Norway (www.uit.no). | en_US |
dc.description | Source at <a href=https://doi.org/10.1038/s41598-018-36854-7>https://doi.org/10.1038/s41598-018-36854-7. </a>© The Author(s) 2019 | en_US |
dc.identifier.citation | Richardsen, E., Andersen, S., Melbø-Jørgensen, C., Rakaee, M., Ness, N., Al-Saad, S. ... Busund, L-T. (2019). MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. <i>Scientific Reports</i>, 9:386. https://doi.org/10.1038/s41598-018-36854-7 | en_US |
dc.identifier.cristinID | FRIDAID 1692066 | |
dc.identifier.doi | 10.1038/s41598-018-36854-7 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/10037/15830 | |
dc.language.iso | eng | en_US |
dc.publisher | Nature Research | en_US |
dc.relation.journal | Scientific Reports | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710 | en_US |
dc.title | MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |